References
- Tariq M, Ware SM. Importance of genetic evaluation and testing in pediatric cardiomyopathy. World J Cardiol 2014;6:1156-65. https://doi.org/10.4330/wjc.v6.i11.1156
- Callis TE, Jensen BC, Weck KE, Willis MS. Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn 2010;10:329-51. https://doi.org/10.1586/erm.10.13
- Roma-Rodrigues C, Fernandes AR. Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet 2014;7:195-208.
- Willott RH, Gomes AV, Chang AN, Parvatiyar MS, Pinto JR, Potter JD. Mutations in Troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function? J Mol Cell Cardiol 2010;48:882-92. https://doi.org/10.1016/j.yjmcc.2009.10.031
- Luedde M, Ehlermann P, Weichenhan D, et al. Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2) mutation. Cardiovasc Res 2010;86:452-60. https://doi.org/10.1093/cvr/cvq009
- Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003;111:209-16. https://doi.org/10.1172/JCI200316336
- Vallins WJ, Brand NJ, Dabhade N, Butler-Browne G, Yacoub MH, Barton PJ. Molecular cloning of human cardiac troponin I using polymerase chain reaction. FEBS Lett 1990;270:57-61. https://doi.org/10.1016/0014-5793(90)81234-F
- Bhavsar PK, Brand NJ, Yacoub MH, Barton PJ. Isolation and characterization of the human cardiac troponin I gene (TNNI3). Genomics 1996;35:11-23. https://doi.org/10.1006/geno.1996.0317
- Gomes AV, Liang J, Potter JD. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem 2005;280:30909-15. https://doi.org/10.1074/jbc.M500287200
- Kobayashi T, Solaro RJ. Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. J Biol Chem 2006;281:13471-7. https://doi.org/10.1074/jbc.M509561200
- Davis J, Wen H, Edwards T, Metzger JM. Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathylinked troponin I mutants. J Mol Cell Cardiol 2008;44:891-904. https://doi.org/10.1016/j.yjmcc.2008.02.274
- Perry SV. Troponin I: inhibitor or facilitator. Mol Cell Biochem 1999;190:9-32. https://doi.org/10.1023/A:1006939307715
- Lang R, Gomes AV, Zhao J, Housmans PR, Miller T, Potter JD. Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy. J Biol Chem 2002;277:11670-8. https://doi.org/10.1074/jbc.M108912200
- Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84. https://doi.org/10.1056/NEJM200004133421502
- Webber SA, Lipshultz SE, Sleeper LA, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation 2012;126:1237-44. https://doi.org/10.1161/CIRCULATIONAHA.112.104638
- Zou Y, Wang J, Liu X, et al. Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy. Mol Biol Rep 2013;40:3969-76. https://doi.org/10.1007/s11033-012-2474-2
Cited by
- Phenotypic diversity identified by cardiac magnetic resonance in a large hypertrophic cardiomyopathy family with a single MYH7 mutation vol.8, pp.None, 2017, https://doi.org/10.1038/s41598-018-19372-4
- Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure vol.51, pp.10, 2021, https://doi.org/10.4070/kcj.2021.0154
- Phosphoproteomic Analysis and Protein-Protein Interaction of Rat Aorta GJA1 and Rat Heart FKBP1A after Secoiridoid Consumption from Virgin Olive Oil: A Functional Proteomic Approach vol.69, pp.5, 2021, https://doi.org/10.1021/acs.jafc.0c07164